Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $13.3 million.

  • Biofrontera's Operating Expenses fell 505.3% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 10.78%. This contributed to the annual value of $54.5 million for FY2024, which is 390.67% down from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Operating Expenses is $13.3 million, which was down 505.3% from $14.1 million recorded in Q2 2025.
  • Biofrontera's Operating Expenses' 5-year high stood at $20.4 million during Q3 2021, with a 5-year trough of $8.0 million in Q3 2022.
  • For the 5-year period, Biofrontera's Operating Expenses averaged around $13.1 million, with its median value being $13.4 million (2024).
  • As far as peak fluctuations go, Biofrontera's Operating Expenses soared by 26524.3% in 2021, and later tumbled by 6105.0% in 2022.
  • Over the past 5 years, Biofrontera's Operating Expenses (Quarter) stood at $11.0 million in 2021, then soared by 42.69% to $15.8 million in 2022, then decreased by 8.27% to $14.5 million in 2023, then decreased by 1.31% to $14.3 million in 2024, then decreased by 7.04% to $13.3 million in 2025.
  • Its last three reported values are $13.3 million in Q3 2025, $14.1 million for Q2 2025, and $13.1 million during Q1 2025.